Athira Pharma, Inc.
ATHA
$0.36
$0.01885.51%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | -20.47% | -21.65% | -21.08% | -18.69% | -2.57% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -37.11% | -23.86% | -6.31% | 11.92% | 24.51% |
Operating Income | 37.11% | 23.86% | 6.31% | -11.92% | -24.51% |
Income Before Tax | 31.37% | 17.62% | 9.38% | -5.30% | -13.38% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 31.37% | 17.62% | 9.38% | -5.30% | -13.38% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 31.37% | 17.62% | 9.38% | -5.30% | -13.38% |
EBIT | 37.11% | 23.86% | 6.31% | -11.92% | -24.51% |
EBITDA | 37.39% | 24.04% | 6.36% | -12.00% | -24.69% |
EPS Basic | 32.17% | 18.55% | 10.26% | -4.47% | -12.51% |
Normalized Basic EPS | 36.79% | 23.22% | 4.42% | -16.58% | -26.07% |
EPS Diluted | 32.17% | 18.55% | 10.26% | -4.47% | -12.51% |
Normalized Diluted EPS | 36.79% | 23.22% | 4.42% | -16.58% | -26.07% |
Average Basic Shares Outstanding | 1.42% | 1.21% | 0.98% | 0.83% | 0.80% |
Average Diluted Shares Outstanding | 1.42% | 1.21% | 0.98% | 0.83% | 0.80% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |